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e under thbstract Serological tests for tuberculosis are inaccurate and WHO has recom-
mended against their use. Although not used by the Revised National TB Control Pro-
gramme (RNTCP), serodiagnostics are widely used in the private sector in India. A
root-cause analysis was undertaken to determine why serological tests are so popu-
lar, and seven root causes were identified that can be grouped into three categories:
technical/medical, economic, and regulatory. Technical/medical: RNTCPs current
low budget does not allow scale-up of the newer, WHO-endorsed technologies.
Thus, under the RNTCP, most patients have access to only smear microscopy, a test
that is insensitive and underused in the private sector. Because there is no accurate,
validated, point-of-care test for TB, serological tests meet a perceived need among
doctors and patients. Economic: While imported molecular or liquid culture tests
are too expensive, there are no affordable Indian versions on the market, leaving
serological tests as the main alternative. Although serological tests are inaccurate,
various players along the value chain profit from their use, and this sustains a market
for these tests. Regulatory: TB tests are poorly regulated and a large number of
serological kits are on the market. Private healthcare in general is poorly regulated,
and doctors in the private sector are outside the scope of RNTCP and do not neces-
sarily follow standard guidelines. A clear understanding of these realities should
facilitate market-based strategies that can help replace serological tests with accu-
rate, validated tools.
ª 2012 Ministry of Health, Saudi Arabia. Published by Elsevier Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/2
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While serological tests work well for several infec-
tious diseases, existing serological tests for tuber-
culosis [TB] (both ELISA and rapid lateral flowabia. Published by Elsevier Ltd.
creativecommons.org/licenses/by-nc-nd/4.0/).
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useful, as shown by a 2007 meta-analysis [1] and
confirmed by an independent evaluation of 19 com-
mercial rapid tests by the World Health Organiza-
tion (WHO) the following year [2]. Unfortunately,
the evidence from these studies was not translated
into policy at that time.
While most regulatory bodies have mechanisms
to withdraw or ban dangerous drugs and vaccines,
there is little awareness about the human and eco-
nomic consequences of bad diagnostics [3]. An-
other reason for the initial inaction was possibly
the perception that these tests were rarely used.
In reality, these tests are widely abused in the pri-
vate sector in countries such as India, with at least
1.5 million serological tests performed in India
every year [4].
Every major private laboratory in India offers TB
serological tests, mostly ELISA kits imported from
developed countries that do not allow these tests
to be used on their own TB patients. The problem
extends far beyond India. These tests are available
in the private sector in at least 17 of the 22 highest
TB-burden countries, from China to South Africa to
Afghanistan [4].
In 2010, WHO recognized this widespread prob-
lem and convened an Expert Group to formulate
a policy. The Expert Group considered an updated
meta-analysis of test performance and a cost-
effectiveness analysis. The meta-analysis synthe-
sized evidence from 92 studies and concluded that
commercial serological tests remain inconsistent
and inaccurate, supported only by data of very
low quality [5]. The cost-effectiveness study found
that serology results in more human suffering, sec-
ondary infections, and false-positive diagnoses
than sputum smear microscopy, while increasing
per-patient costs to the Indian TB control sector
[6]. At $10–$30 per test, the costs of testing (often
borne by patients who pay out-of-pocket), plus the
cost of TB drugs wasted on treating patients with
false-positive results, rival the entire Revised Na-
tional TB Control Programme (RNTCP) annual bud-
get of $65 million.
Based on this evidence, the WHO released a pol-
icy on 20 July 2011 concluding that since ‘‘the
harms/risks [of commercial serodiagnostic tests]
far outweigh any potential benefits (strong recom-
mendation)...these tests should not be used on
individuals suspected of active pulmonary or ex-
tra-pulmonary TB, irrespective of their HIV status
[7]’’.
While the WHO policy provides global guidance,
it is up to high-burden countries to implement this
policy. Immediately following the WHO policy
announcement, the Indian RNTCP issued anadvisory against TB serological tests, endorsing
the WHO policy recommendations [8]. The chal-
lenge, however, is the Indian private sector, which
manages nearly half of all TB cases in India [9].
It is well known that TB management practices
in the private sector vary widely, often deviating
from national and international standards [10–
15]. For example, private providers in India are
known to underuse sputum smears, and overuse
chest X-rays and serological tests for active TB
detection [11,14,16–18]. Prescription studies and
TB drug market analyses show use of irrational drug
regimens, significant overuse of TB drugs, and easy
access to TB drugs over-the-counter, without pre-
scriptions [10,13,19,20].
In this context, the following research will ex-
plore why serological tests are so popular in the
private sector and what factors have paved the
way for their widespread use. The lessons learned
from the serology story can be applied to vali-
dated, WHO-endorsed technologies that need to
be scaled-up.
2. Materials and methods
2.1. Data collection
The research began by reviewing the literature
on TB diagnostic and management practices in
the Indian private sector, as well as the studies
on the quality of private healthcare. The pub-
lished evidence combined with the insights of
the following research was used to formulate
the survey and conclusions [10–14,16,17,20–23].
Face-to-face or telephone interviews were con-
ducted with 41 stakeholders in India: private doc-
tors and private hospital laboratory staff (N = 11),
private stand-alone laboratories (N = 7), distribu-
tors of diagnostic tests (N = 7), manufacturers of
diagnostic tests (N = 7), government hospital doc-
tors (N = 4), and NGOs working in TB (N = 5). Over
90% of respondents had a minimum of 10 years
experience in the diagnostics/healthcare sector
in India.
Key informant interviews were performed be-
tween March and May 2011, before the formal pub-
lication of the WHO serology policy in July 2011;
77% of the interviews were done in person. Respon-
dents were generally from metropolitan areas of
Delhi, Bangalore, Mumbai and Chennai. All key
informants were assured that their identity would
not be revealed in any research reports. Informants
were selected based on a prior landscape analysis
of TB diagnostics in India [3,18], and new key infor-
mants were identified by snowballing from the
interviews.
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All respondents were asked the following ques-
tions: ‘‘Why is ELISA (TB serological tests) the ma-
jor test for TB in the private sector? Could you list
all possible reasons?’’ Each answer was followed by
asking why each of the reasons existed. They were
also asked: ‘‘What are the interests of the stake-
holders (e.g. economic, clinical, etc.) of TB diag-
nostics in India?’’ Interviewees were prompted to
speak about their personal experience with TB
diagnostics (rather than hearsay). Data were also
collected on cost of various TB tests from diagnos-
tic companies, distributors and private
laboratories.
2.3. Data analysis
2.3.1. Root-cause analysis (RCA)
RCA is a tool designed to help identify not only
what and how an event occurred, but also why it
happened [24]. RCA prevents the most visible cau-
sal factor from getting all the attention. It charts
out the causes and their effects for a particular
problem. Root causes are [24]: (a) specific underly-
ing causes; (b) those that can reasonably be identi-
fied; (c) those that can be fixed; and (d) those for
which effective recommendations for preventing
recurrences can be generated. The process of for-
mulating the RCA involves data collection, cause
charting, root-cause identification, recommenda-
tion generation and implementation [24]. The fol-
lowing proposed recommendations are either
directly from the authors or were suggested by
interviewees.
Current Reality Tree (CRT) is a type of RCA [25].
CRT allows incorporating multiple problems into a
single diagram. It also enables identifying causal
interdependency, intermediate factors and feed-
back loops [25]. Doggett further explains the CRT
as follows: ‘‘The CRT was designed to show the
current state of reality as it exists in a system. Typ-
ically, arrows in the CRT signify a sufficiency rela-
tionship between the entities. Sufficiency implies
that the cause is, in fact, enough to create the ef-
fect. Entities that do not meet the sufficiency cri-
teria are not connected. The relationship
between two entities is read as an ‘‘if-then’’ state-
ment such as, ‘‘If [cause statement entity], then
[effect statement entity]’’ [25].
In addition, the CRT uses a unique symbol, the
oval or ellipse, to show relationships between
interdependent causes. These relationships were
constructed by the authors, based on the inter-
views and published literature. Because the CRT
is based on sufficiency, there may be cases whereone cause is not sufficient by itself to create the
proposed effect. Thus, the ellipse shows that mul-
tiple causes are required for the produced effect.
3. Results
3.1. Quantitative analysis of interviews
Fig. 1 summarizes the responses to the question:
‘‘Why is ELISA (TB serological test) the major test
forTB in theprivate sector?Could you list all possible
reasons?’’Overall, a lackofawarenessamongdoctors
regarding TB diagnosis was themost frequently given
reason. This was formulated either as ‘‘doctors igno-
rance’’ about the lack of accuracy of serological
tests, or by pointing out that RNTCP and the govern-
ment had failed to educate the private doctors. This
reason was followed by referral fees (incentives)
which encourage the use of serodiagnostics. Doctors
who request serological tests are often offered by
the private laboratories about 20–50% of the price
(i.e., between 150 and 300 rupees) paid by the pa-
tient. Redundant testing where serology is one com-
ponent in a battery of lab tests, a lack of accurate
rapid tests with sensitivity higher than sputum smear
(preferably also blood-based) and patients afford-
ability were some other leading reasons.
3.2. Economics of TB diagnostics from the
laboratory perspective
This analysis was undertaken to understand why
private-for-profit laboratories prefer serological
tests. As shown in Table 1 (based on data collected
from laboratories), there are striking disparities in
prices of TB tests across private labs (100% varia-
tion) and the informants were unable to disaggre-
gate the margins and specific non-reagent costs.
In fact, when pricing a new test, the informants
indicated that laboratories would typically con-
sider 4–7-fold increase versus the reagent price
as well as patients willingness to pay for a given
test. Private laboratories also factor in the refer-
ral/incentive fees that they would need to pay
back to referring doctors. These factors collec-
tively result in inflation of the price of diagnostics
for patients.
Overall, sputum smears are the least expensive
tests and also have the lowest profit margin. There-
fore, private laboratories do not actively promote
them. At the other extreme, liquid cultures and
molecular tests (e.g. polymerase chain reaction
[PCR]) ensure higher profits to both doctors and
laboratories, but are rarely prescribed by doctors
because patients find them too expensive. In gen-
eral, laboratories are reluctant to bear very high
Figure 1 Bar chart showing the frequency of all replies to the question: ‘‘Why is ELISA (and other serological tests)
the major test for TB in the private sector?’’ (N = 33 respondents with direct experience in TB diagnostics).
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ing of technical staff without certainty that they
would have a sufficient volume of samples to re-
coup the investment. Scarcity of laboratories
which perform liquid culture and PCR tests for TB
and infrequent prescription of these tests by doc-
tors are linked by a positive feedback loop.
Serological tests have an intermediate price tag
and a modest profit margin, but because of the
large volume (a large number of requests from doc-
tors) and low investment requirement (many labo-
ratories have ELISA readers that are used for a
variety of tests), private laboratories find them
attractive. Serology gives higher profit margins
than sputum smears and is easy to perform with
minimal investment. Further, ELISA tests are pre-
scribed frequently by doctors, many of whom con-
sider them to be a ‘‘modern or better alternative’’
to the antiquated sputum microscopy. Widespread
availability of ELISA tests for TB in many privatelaboratories and frequent orders for the test by
doctors are linked by a positive feedback loop.
Along the delivery chain of the serological tests
for TB, private pathology laboratories and doctors
draw the highest economic gains from the test.
Others who profit include diagnostic manufacturers
and distributors.
3.3. Why are sputum smears unpopular in
the private sector?
During the interviews, additional questions were
asked in order to identify clinical, practical, eco-
nomic and cultural reasons (Table 2) why sputum
smears are unpopular. These range from the poor
sensitivity of smears, lack of utility in extrapulmo-
nary and smear-negative TB, to low profit margins
for laboratories, low referral fees for doctors,
and stigma associated with sputum testing and
TB. Many of these reasons provide insights into
Table 1 Economics of TB diagnostics in private sector laboratories in India.
Characteristics per
single test
Sputum Smears
(Z-N and fluorescent)
ELISA
(serological tests for
TB)
Automated liquid
culture
PCR-based molecular
tests
Cost of reagents and
consumables
(Rupees)
15 90 for TB IgG 200 (detection) 300 Gel PCR
90 for TB IgM 500 (detection
and drug
sensitivity
testing)
500 RT-PCR
1100 Line
probe assay
1400 GeneXpert
Margin + non-reagent
costs to the lab
(Rupees)#
85–125 310–510 700–2500 700–2100
Price to the patient
(Rupees)
100–150 400–600 for
a single antibody
900–1500
(detection)
1000 Gel PCR
800–1200 for
TB IgG + TB IgM
2000–3000
(detection and
drug sensitivity)
1500 RT-PCR
2500 Line
probe assay
3500 GeneXpert
Time spent by
technician
45 min 3–4 h* 1 h* 3–4 h*
Technician training
time required
5 days (min) 2 days 2–3 days 2 days–2 weeks
Requirement of
instrumentation
(Rupees)
Microscope ELISA reader (90,000) Instrument
(100,000–150,000)**
PCR equipment,
RT-PCR,
GeneXpert
Requirement of
special working
conditions
Moderate
biosafety
Minimal biosafety BSL III Moderate biosafety,
Separate room for
each reaction step
(except GeneXpert)
# ‘‘Margin + non-reagent costs’’ value is aggregated because respondents were unable to clearly state the corresponding
amounts. Instead, the labs said that when calculating a price of a test to patients, they would typically assume 4–7-fold increase
versus the cost of a reagent.
* Several tests can be prepared at the same time (limited by centrifuge/machine capacity).
** Reagent rental possible (e.g. highly discounted instrument, obligation to do 10 samples/day for sensitivity testing during
3 years).
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attractive to doctors, patients and laboratories in
India. Blood-based tests are done for a variety of
diseases, and not easily linked with TB and the stig-
ma surrounding the disease. Unlike sputum smears
where patients are required to give multiple spec-
imens, a single blood draw is adequate for serolog-
ical tests, and results are much faster than smear
microscopy. More importantly, serological tests
are economically more profitable for both labora-
tories and doctors, as compared to sputum smears.
3.4. Root causes for the success of TB
serological tests in India
The RCA analysis suggested seven root causes
(Fig. 2) that can be grouped into three categories:
technical/medical, economic, and regulatory.
From a technical/medical perspective, RNTCP is
currently underfunded and perceived to be focused
only on sputum smear-positive cases. Indeed, mostpatients can only access sputum smears in the pub-
lic sector. Private doctors therefore do not think
the RNTCP can offer anything more than just smear
microscopy for their patients, and they also believe
that smears are not adequate for the types of cases
they encounter (e.g. extrapulmonary TB and
smear-negative disease). Private doctors also be-
lieve that smears are insensitive and inconvenient
for patients. More importantly, TB culture facilities
are not widely available via the RNTCP, and there is
a general lack of trust in the quality of govern-
ment-run services. Thus, private doctors are reluc-
tant to refer their patients to RNTCP for diagnostic
workup, even if it is free for patients. Also, be-
cause there is no accurate, WHO-endorsed, simple
point-of-care test for TB, serological tests meet a
perceived need among doctors for a rapid, blood-
based test, especially for extrapulmonary TB,
smear-negative TB, and for investigation of chronic
fevers and relevant conditions (e.g. infertility in
women).
Table 2 Reasons why sputum smear microscopy is not popular in the private sector in India.
Doctors Patients Labs
Clinical Doctors think smears are not
sensitive and are antiquated
Some patients are not able to
produce sputum
Labs think that smears are
antiquated and are keen on
replacing them with a more
modern technology
Sputum-based tests are not
suitable for diagnosis of
Extrapulmonary TB, smear-
negative and childhood TB
Practical Unlike tests such as chest X-ray,
doctors cannot directly see the
smear result (have to rely on lab
interpretation)
Patients ask for a test that
requires a single visit
ELISA is a ‘‘bench’’ technique
and is perceived as ‘‘cleaner’’
than smear
Doctors have been told that 3
sputum specimens need to be
examined and this is not
convenient for patients and
drop-outs are likely
Technician training is necessary
for microscopic examination of
smear.
In case of respiratory infections
or chronic fevers, patients are
giving blood sample for blood
counts / ESR and ELISA can be
performed on the same sample
RNTCP does not reach the
private labs to give guidance on
the quality assurance for
sputum smears
Economic Smears are cheap and referral
fees are too low (referral fees
to doctors are higher for x-rays,
serology, PCR, etc.)
Some patients are ready to pay
more than approximately 100 Rs
for the smear if they believe
that they are offered a better
test
Smears are cheap and give low
profit margins so labs do not
promote them to doctors
Doctors want to start TB
treatment to keep patients with
them for 6 months, and because
smear is perceived as having
low sensitivity, they do not like
to use it
Cultural Doctors want to be perceived as
‘‘modern’’ by the community
and refrain from antiquated
techniques
Patients associate sputum with
TB and that increases their fear
of stigmatization; so, patients
may prefer a blood-based test
over sputum testing
Labs want to be perceived by
doctors and by patients as
‘‘modern’’ and refrain from
antiquated techniques
44 S. Jarosławski, M. PaiFrom an economic perspective, several players
are given incentives to use serological tests along
the value chain, and this sustains their market. In
contrast, there are no affordable molecular or li-
quid culture tests on the Indian market. This means
such tests are mostly imported and are very expen-
sive for Indian patients. Indeed, tests such as auto-
mated liquid culture (e.g. MGIT 960, BD, Sparks,
USA) and molecular tests (e.g. Xpert MTB/RIF, Cep-
heid Inc., Sunnyvale, CA, USA) cost as much as
$50–$100 in the private market, and these tests
are rarely used because of the high costs. In this
context, serology is perceived by doctors as a
‘‘more affordable and convenient’’ alternative.
From a regulatory perspective, because private
medical care is poorly regulated, doctors in the pri-vate sector are outside the scope of RNTCP and do
not feel compelled to follow RNTCP guidelines.
Apart from the RNTCP guidelines, there are no
other national TB guidelines for private doctors to
follow. While the International Standards for TB
Care are available [15] and endorsed by the RNTCP,
there is no easy mechanism to implement or man-
date them in the private sector. In the past, Indian
doctors were not required to get re-certified or
even undergo continuing medical education (CME)
to keep up-to-date with the latest guidelines. This
may be changing with the Medical Council of India
(MCI) proposing new rules that require mandatory
CME credit hours to maintain their registration.
For many private doctors, a major source of educa-
tional material is material handed out by
Figure 2 Current Reality Tree which identifies the root causes of the widespread use of TB serodiagnostics in the
private sector in India.
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tives. Thus, some private doctors may be genuinely
unaware that serological TB tests are not recom-
mended by any agency. They may be using these
tests in good faith, and not necessarily driven by
economic incentives.
Regulation of in vitro diagnostics (IVDs) is
weak in India. The Central Drugs Standard Control
Organization (CDSCO) classifies IVDs as ‘‘critical’’
or ‘‘non-critical’’ with only a few tests (e.g. HIV,
hepatitis B & C) related to blood safety (in blood
banking) considered ‘‘critical’’. TB tests are not
classified as ‘‘critical tests’’ by the Drug Control-
ler General of India (DCGI), and this allows for
entry and sale of suboptimal serodiagnostics with
very little independent validation [18]. In fact, a
large number of imported and domestic serologi-
cal kits are readily available in the market and
various players have incentives to use them
[4,6]. Many of the kits on the market claim to
have near-perfect sensitivity and specificity,
without published data to support such claims
[5,6].Lastly, the private laboratory testing market in
India is also poorly regulated. A majority of Indian
labs are not accredited or certified by a quality
assurance body [18], and there are few require-
ments for establishing and running laboratories,
although this may improve with the enforcement
of the Clinical Establishments Act [26]. There is
no transparency in pricing, and practices such as
referral fees are well documented [27].
4. Discussion
Mismanagement of TB is bad for the individual pa-
tient. For example, false-positive diagnoses result
in unnecessary drug treatment and side effects,
personal financial losses, and public resource utili-
zation [6]. Mismanagement is equally bad from a
public health perspective because every misman-
aged or undiagnosed TB patient serves as a source
for new infections in the community [3]. Wide-
spread abuse of inappropriate tests can prevent
the use of good diagnostics, and this is a major
challenge for implementation of new diagnostics.
Table 3 Recommendations for addressing the root causes identified for success of serological tests in India.
Root cause Recommendations
RNTCP is underfinanced/focused only on the control of
smear-positive TB
(1) The overall budget of RNTCP must be increased for the
next phase (2012–2017)
(2) The next phase of RNTCP must finance currently available
best diagnostic techniques for smear-positive TB , extra-
pulmonary-TB and MDR-TB (liquid culture, molecular
assays)
Doctors in the private sector beyond the scope of
RNTCP/lack of other national TB guidelines
(1) Involve private doctors in the process of development of
RNTCP policies and guidelines
(2) Develop national guidelines for diagnosis and manage-
ment of all types of TB (broader than RNTCP guidelines,
aiming at all sectors)
(3) Disseminate the guidelines actively to ensure their pene-
tration in the private sector
TB is not listed as a ‘‘critical disease’’ by CDSCO & DCGI (1) Reclassify TB tests as ‘‘critical devices’’
(2) Re-design the process of licensing so that it ensures that
the tests are validated against a reference standard in
national centres (not only manufacturing license)
(3) CDSCO must ban sales of currently available TB serologics
due to high public health importance and oblige NABL to
respect the ban in accredited labs
(4) RNTCP should advise DCGI on acceptable performance
characteristics for all TB tests (like NACO did for rapid
HIV tests)
Lack of alternative rapid, simple or blood-based test for
TB (all types of TB) on the market
(1) Encourage R&D in the Indian industry by providing an
advance promise of prospective purchase by the govern-
ment in case the test passes external validation.
(2) Protect Indian market by eliminating inaccurate TB tests
from the market through improved CDSCO regulation
(3) Encourage (Indian) industry to undertake external valida-
tion of existing Indian commercial PCR kits, and support
development of high quality generic molecular tests and
automated liquid cultures
No affordable instrumentation/ reagents available for
liquid culture or PCR on the market
Private diagnostics market in general has weak
regulation (i.e. no transparency in pricing, widespread
referral fees)
(1) Put protection of patients expenditure at the centre of
the regulation of the private sector
(2) Regulate prices of TB diagnostics by reimbursing good
procedures to the private sector at a fixed price. Reim-
bursement to the private sector should also result in
weaker incentive for labs to rely on referral fees. Refer-
ence pricing (fixed as the reimbursement fee by the gov-
ernment) would homogenize prices across private labs in
India
(3) Reinforce the ban of referral fees
(4) Overall, improve regulation of private healthcare in India
(by implementing Clinical Establishments Act)
Government financing of healthcare is largely insufficient
in India
(1) Overall expenditure on health must be increased.
Patients access to high-quality diagnostics will not
improve unless a dramatic expansion takes place of reim-
bursement of such techniques within RNTCP and to pri-
vate sector
(2) If national health care expenditure is to be increased,
this should not be consumed only by reimbursement of
drugs, but also by diagnostics
CDSCO, Central Drugs Standard Control Organization; DCGI, Drug Controller General of India; GOI, Government of India; RNTCP,
Revised National Tuberculosis Control Programme; NABL, National Accreditation Board for Testing and Calibration Laboratories;
NACO, National AIDS Control Organization.
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ture dominates the financing of health care costs
and where such spending is one of the major rea-
sons for people sliding into indebtedness [28], theuse of inaccurate tests might have a negative im-
pact on household budgets of many people.
For each of the root causes identified, several
recommendations are suggested (Table 3).
Table 4 If a new diagnostic is to succeed in the Indian private market, then the popularity of commercial serology tests in
India suggests that it should have the following characteristics.
Test characteristic Rationale
Should be perceived by doctors as a more sensitive
and sophisticated test than sputum smears
Doctors often fear under-diagnosis of TB. They do not
want to miss a TB case for ethical as well as monetary
reasons (the patient will be under their treatment for
months). They fear that their reputation will suffer if
they offer to patients sputum smears or refer them to
an RNTCP centre
Should be a rapid test – either a point-of-care* test
which can be done in the clinic or a laboratory test
that can produce results within the same day
Given the doctor-centric nature of the private
healthcare, doctors need to draw monetary benefit
from the procedure. A rapid test result ensures that
patients will stay with the doctors and will not drop-
out. Tests such as cultures are very unpopular among
doctors because of the lengthy time delays and
because they rarely influence doctors clinical
decisions
Should be done on blood or urine sample and a single
test should be sufficient for diagnosis
Stigma related to TB makes sputum a less desired
sample. Also, patients with suspected TB or chronic
fevers often give blood samples for other lab tests
(ESR, CBC) and this will make a test based on sputum
disadvantaged as compared to a test which can be
done on the same blood sample. Also, doctors might
be afraid that patients will not show up for a second
visit if more than one test is needed to make
diagnosis
Should be suitable for the detection of
extrapulmonary TB
Neither sputum smear nor X-ray is suitable for
detection of extrapulmonary TB. There is a highly
unmet need for a test for this type of TB (genito-
urinary TB in particular because it is considered a
major cause of infertility in India).
Labs should not need to make big investments in
infrastructure/equipment
Labs might be reluctant to invest in equipment/
facility if they are not certain of a good volume of
samples. This applies also to reagent rental schemes
which oblige labs to buy a certain amount of reagents
in a given time
It should not be too cheap or too expensive, but be in
the middle range of about rupees 500 (price to the
patient) in the private sector
The current private health care system is to a large
extent driven by referral fees which are about 20–
50% of the price which patients pay for the test. Any
diagnostic test to be successful in the current
scenario must assure a referral fee to doctors in a
range of 150–300 Rupees per patient. Patients
affordability dictates that the test should not
significantly exceed rupees 500 (approx. 10 US$) or so
* Most Indian doctors do not perform any testing themselves in the clinic and they prefer to send patients to the labs, either
because they are too busy to be doing testing, or they are nervous about interpreting rapid tests themselves. Also, sending patients
to labs is much easier because kickbacks are assured. If they do the POC test themselves, then they have to charge the patient their
consultation fees PLUS the rapid test fees and that might be seen as a problem for patients (who will not mind paying the lab). So,
contrary to what is often thought, a POC test in India might not actually get used at the point of care.
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and scaling-up new, validated diagnostics within
RNTCP will enable more Indian TB patients to get
quality-assured diagnostic work-up, and might help
address the perceived need of doctors for im-
proved diagnostic tests. Because expanding DOTScoverage and engaging all providers is critical for
RNTCP, the programme should make an effort to
understand why patients prefer the private sector,
and why so many doctors keep referring patients to
private diagnostic laboratories and not to the
RNTCP. Lack of trust in quality of public services
48 S. Jarosławski, M. Paiand limited availability of diagnostics other than
sputum smears are issues which the RNTCP can
and must address.
Indeed, Indias annual healthcare spending con-
tinues to remain one of the lowest in the world.
Not surprisingly, the RNTCP budget is low, even
though modeling suggests that TB control has
been a very cost-effective strategy for improving
the health status of Indias population, with
exceptional return on investment from a societal
perspective [29]. It has been estimated that the
scale-up of TB control in India accounted for just
1.0% of public expenditure on health over the
period 1997–2006 [29]. Thus, the RNTCPs cur-
rent low budget does not allow widespread
scale-up of sophisticated, WHO-endorsed technol-
ogies. For example, only a small fraction of In-
dian patients has access to liquid cultures and
line probe assays. In 2010, India, together with
DR Congo and Bangladesh, had the poorest access
to culture facilities among high-burden countries
(less than 0.1 per 5 million of population) [30].
A large proportion of TB patients therefore end
up seeking private medical care, even if it meant
higher expense for patients who mostly pay out-
of-pocket [9].
The RNTCP has clearly made great progress in
the past decade and has successfully scaled-up
the DOTS strategy to cover 100% of the Indian pop-
ulation [29]. The program is currently preparing to
enter a new phase, the National Strategic Plan
(NSP), for the period 2012–2017. For this new
phase, significantly higher budgets have been re-
quested. Scale-up of new diagnostics is a central
part of this plan, along with greater engagement
of the private sector, which must be involved in
creating RNTCP guidelines, and thereby have great-
er ownership. Creation of an ‘‘Indian Standards for
TB Care,’’ along the lines of the ‘‘International
Standards for TB Care’’, for both public and private
sectors, might help in overcoming the reluctance
of private doctors to follow RNTCP guidelines,
which they do not perceive as their own.
The central issue to appreciate is that India has
the largest private health sector in the world, with
60–80% of health care sought in the private sector,
and a health care market that is worth billions of
rupees [31]. Despite its enormous size and impor-
tance, this sector is largely unregulated [31],
although the Clinical Establishment Act 2010 at-
tempts to address this tricky and controversial is-
sue [26]. This Act is yet to be implemented and
has been opposed by the private medical sector
in India [32]. Full implementation of this Act should
be a major priority for the Indian government and
ministry of health.Furthermore, the private health care market in
India is heavily doctor-centric. The doctor is the
sole decision maker in determining the tests that
a patient will receive. While not all private doctors
accept kickbacks and order unnecessary tests, the
private healthcare system is influenced by mone-
tary gains, with wide variations in practice quality
[20–23]. Thus, any potential solution must address
this reality, and take into account well-docu-
mented issues such as referral fees [27,33], unnec-
essary interventions [34], and widespread
antibiotic abuse [20,35,36].
TB serological tests can bring economic benefits
to doctors, although not all laboratories offer
incentives and not all doctors accept incentives.
Similar profit to doctors must be assured for good
practice. This could be a referral fee paid to them
by RNTCP for referral to their facility or to an
accredited private laboratory which only performs
WHO-endorsed tests. Further, free DOTS medicines
could be made available to patients in the private
sector so that doctors do not need to be concerned
about losing their patients to the RNTCP.
The government should actively educate the
public on the prevalence of referral fees in the pri-
vate laboratory sector and empower patients to
choose service providers. For that, patients must
be enabled to judge laboratory quality on their
own and make their choice based on quality and
price. They must be aware of the accreditation of
laboratories and must have a reasonable choice
of accredited laboratories. Only then fair price
competition among laboratories can be promoted.
Unfortunately, there is currently no way for pa-
tients to get data on quality of laboratories or doc-
tors or hospitals in India. There is no objective
metric or ranking system to judge quality of medi-
cal care in the country. Quality Council of India
[37], an autonomous body of the Department of
Industrial Policy and Promotion, Govt. of India,
must address this by establishing and improving na-
tional accreditation structures, including National
Accreditation Board for Testing and Calibration
Laboratories (NABL), and National Accreditation
Board for Hospitals and Healthcare Providers
(NABH).
A majority of Indian laboratories are not accred-
ited or certified by a quality assurance body [18].
Currently, less than 250 Indian laboratories out of
an estimated 50,000 have NABL accreditation
[38]. There are very few requirements as to mini-
mal training qualifications for persons performing
laboratory procedures, and skilled laboratory tech-
nicians are scarce in India. Making NABL accredita-
tion a mandatory requirement for all laboratories is
a policy worth consideration.
Why are inaccurate tuberculosis serological tests widely used in the Indian private healthcare sector? 49In the current scenario where regulation of IVDs
is virtually limited to the so-called ‘‘critical de-
vices’’ listed by CDSCO, putting TB tests on this list
is essential to remove serological TB tests from the
market. In principle, the recent WHO policy would
make this regulatory action straightforward. In
practice, it will require political will at the level
of the DCGI, high-level support from agencies such
as RNTCP and Indian Council of Medical Research,
and advocacy from patient representatives, civil
society and consumer groups.
If a new diagnostic is to succeed in the Indian
private market, what characteristics should it
have? Based on the lessons learned in this analysis,
we think the new diagnostic should provide rapid
results (e.g. same-day diagnosis), be more sensi-
tive than sputum microscopy, work well with spec-
imens other than sputum (e.g. blood or urine), and
be able to detect extrapulmonary and smear-nega-
tive disease (Table 4). The test should not be too
cheap or too expensive, but rather be in the middle
range of about Rupees 500 [approximately US $10]
(price to the patient) in the private sector, and the
new test should not force labs to make big invest-
ments in equipment, maintenance or training.
5. Conclusion
Although the WHO recommendation is a major pro-
gress in advocating against the use of inaccurate TB
tests, the WHO policy, by itself, is unlikely to
change the reality in the Indian private sector. A
clear understanding of the ground realities and
the root causes should facilitate market-based
strategies that can help replace serological tests
with accurate, validated tools. Our analysis
suggests that increased funding for TB control,
scale-up new diagnostics via the RNTCP, stronger
regulation of the private healthcare sector (includ-
ing improved regulation of TB diagnostics), rapid
development of in-country R&D to bring new diag-
nostic options to the market, and greater engage-
ment of the private health sector with the RNTCP
are critical ingredients for success.
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